TITLE PAGE

Manuscript title:

Risk Factors for Endometrial Cancer: An umbrella review of the literature

O. Raglan, MBBS[1,2], I. Kalliala PhD[1,3*], G. Markozannes MSc[4], S. Cividini MSc[5], M. J. Gunter PhD[6], J. Nautiyal PhD[1], H. Gabra PhD[1,7], E. Paraskevaidis, PhD[8], P. Martin-Hirsch PhD[9,10], K. K. Tsilidis PhD[4,11**], M. Kyrgiou PhD[1,2]

[1] Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Faculty of Medicine, Imperial College London, UK

[2]Queen Charlotte's and Chelsea – Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK

[3] Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

[4] Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece

[5] Independent Researcher in Biostatistics, Como, Italy

[6] Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC), Lyon, France

[7] Early Clinical Development, IMED Biotech Unit, AstraZeneca, Cambridge, UK

[8]Department of Obstetrics and Gynaecology, University of Ioannina, Ioannina, Greece

[9]Department Gynaecologic Oncology, Lancashire Teaching Hospitals, Preston, UK

[10] Department of Biophysics, University of Lancaster, Lancaster, UK

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ijc.31961

[11] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK

[*] **OR and IK are joint first authors**

[**] **MK and KT are joint senior authors**

Corresponding author:

Dr Maria Kyrgiou

Institute of Reproductive and Developmental Biology

Department of Surgery and Cancer

Imperial College London

Room 3006, 3rd Floor

Du Cane Road, W12 0NN, London

Email: m.kyrgiou@imperial.ac.uk

Tel: +44 2075942177, +44 7725623604

Key words: Endometrial cancer; gynaecological oncology; uterine cancer; obesity; risk factors; umbrella review.

Article type: Umbrella Review

Manuscript word count: 4,320 words

Microsoft Word for Mac, version 16.10

ABSTRACT

Although many risk factors could have causal association with endometrial cancer, they are also prone to residual confounding or other biases which could lead to over- or underestimation. This umbrella review evaluates the strength and validity of evidence pertaining risk factors for endometrial cancer.

Systematic reviews or meta-analyses of observational studies evaluating the association between non-genetic risk factors and risk of developing or dying from endometrial cancer were identified from inception to April 2018 using PubMed, the Cochrane database and manual reference screening. Evidence was graded strong, highly suggestive, suggestive or weak based on statistical significance of random-effects summary estimate, largest study included, number of cases, between-study heterogeneity, 95% prediction intervals, small study effects, excess significance bias and sensitivity analysis with credibility ceilings.

We identified 171 meta-analyses investigating associations between 53 risk factors and endometrial cancer incidence and mortality. Risk factors were categorised: anthropometric indices, dietary intake, physical activity, medical conditions, hormonal therapy use, biochemical markers, gynaecological history and smoking. Of 127 meta-analyses including cohort studies, three associations were graded with strong evidence. Body mass index and waist-to-hip ratio were associated with increased cancer risk in premenopausal women (RR per 5kg/m^2 1.49; CI 1.39-1.61) and for total endometrial cancer (RR per 0.1unit 1.21; CI 1.13-1.29), respectively. Parity reduced risk of disease (RR 0.66, CI 0.60-0.74).

Of many proposed risk factors, only three had strong association without hints of bias. Identification of genuine risk factors associated with endometrial cancer may assist in developing targeted prevention strategies for women at high risk.

Novelty and Impact

Endometrial cancer is the most common gynaecological cancer in the developed world. 171 meta-analyses investigating 53 risk factors for endometrial cancer incidence and mortality were reviewed. Strong evidence supported a positive association for high BMI and waist-to-hip ratio; parity conferred reduced risk. Identifying genuine risk factors may enable targeted prevention strategies for high-risk women.

INTRODUCTION

Endometrial cancer is the most common gynaecological cancer and the second most common female malignancy, after breast cancer, in the developed world. [1] In 2012, the number of new cases and deaths due to endometrial cancer worldwide was 319,605 and 76,160 respectively. [1] The age-standardised incidence and mortality rates from endometrial cancer have been rising steadily in most developed countries over the period 1978-2013, which has been attributed mainly to lifestyle factors (e.g., the obesity and diabetes epidemic), increasing age and socioeconomic-driven changes to reproductive factors such as parity.[2] The use of uterine-sparing treatments for dysfunctional menstrual bleeding has also resulted in a reduced number of hysterectomies performed early in life.[3] Endometrial cancer incidence is predicted to continue to rise in the coming decades, in particular among low and middle-income countries.

Several non-genetic risk factors have been associated with an increased risk of endometrial cancer, particularly for the most prevalent histological subtype endometrioid endometrial adenocarcinoma, which include obesity, physical inactivity, excess exogenous oestrogen, insulin resistance,[4] and tamoxifen use after breast cancer,[5-9] whereas daily coffee consumption has been shown to be inversely associated with endometrial cancer.[10-15] Although many of the reported risk factors could have a causal association with endometrial cancer, they could also be over- or underestimated due to residual confounding or other biases, which are common in the epidemiological literature.[16-18] Umbrella reviews can systematically appraise evidence in the published literature by evaluating meta-analyses of multiple putative risk factors on multiple outcomes. Recent umbrella reviews across a broad spectrum of disease outcomes have concluded that only a minority of several published associations have robust data without hints of bias; these included associations between

adiposity,[19] diabetes mellitus and cancer incidence and mortality,[20] among others. [21-24] We performed an umbrella review of systematic reviews and meta-analyses to investigate the strength and validity of the associations between non-genetic risk factors and the risk of developing or dying from endometrial cancer.

METHODS

Literature search and eligibility criteria

We searched PubMed and the Cochrane database of systematic reviews from inception to 2nd April 2018 for systematic reviews and meta-analyses of observational studies that investigated the association between non-genetic risk factors and risk of endometrial cancer development and death (Supplementary Material). We further hand-searched the citations of the retrieved eligible papers to identify additional publications that might have been missed during the initial search and the proceedings of relevant conferences for unpublished data. In this umbrella review the primary analysis focused on cohort studies, representing the best available evidence among observational studies. Sensitivity analyses were conducted including case-control studies.

Inclusion and exclusion criteria

We included systematic reviews with or without meta-analyses of observational epidemiological studies in humans that assessed lifestyle and environmental (non-genetic) risk factors and endometrial cancer incidence or mortality. We excluded studies where endometrial cancer incidence and mortality were not the primary outcomes, studies with benign endometrial pathologies as the primary outcomes of interest (such as fibroids or endometrial polyps), studies exploring the impact of genetic factors as well as studies

assessing prognostic risk factors among women diagnosed with endometrial cancer (Figure 1). [25-53] We further excluded narrative reviews and meta-analyses that had only one study, did not report the necessary study-specific data including the relative risk (RR) and 95% confidence intervals (CI) or the number of endometrial cancer cases and controls or total population. [14, 54-71] Where two or more meta-analyses examined the exact same association, we chose the largest meta-analysis to avoid duplicate assessment of the same primary studies; the concordance between included and duplicate meta-analyses was explored in a sensitivity analysis (Supplementary Material).

Evaluating the strength of evidence by grading criteria

The association of each risk factor with endometrial cancer was graded as strong, highly suggestive, suggestive or weak evidence. To be included in the 'strong evidence' group, the meta-analysis had to present a p-value of the random effects model smaller than 10^{-6}, a threshold that might substantially reduce false positive findings,[72-74] include more than 1,000 cancer cases, have an I^2 for heterogeneity less than 50%, the 95% prediction intervals should exclude the null value, and there should be no indication of small study effects or excess significance bias. Similarly, to satisfy the criteria for inclusion into the 'highly suggestive' group, meta-analyses needed a random effects P value smaller than 10^{-6}, include more than 1,000 cases, and have a nominally statistically significant largest study (i.e. $p<0.05$) in the meta-analysis. A 'suggestive' association should meet the following criteria: random effects P smaller than 10^{-3}, and more than 1,000 cases. Any remaining meta-analyses where the p-value of the random effects model was nominally statistically significant were considered to present weak evidence. Sensitivity analyses were conducted after further applying the credibility ceiling threshold analysis to account that a single observational study cannot give

more than a maximum certainty, c% (credibility ceiling), that the true effect size is in a different direction from the one suggested by the point estimate [75] (Supplementary Material).

Evaluation of the quality of included meta-analyses

We assessed the strength and quality of all included meta-analyses using the AMSTAR tool, which uses 11 criterion items to measure the methodological quality of systematic reviews.[76] If the specific criterion is met, one point is allocated. An overall score relating to review quality is then calculated using the sum of the individual scores. A review scoring above 8 is considered high quality, 4 to 7 is a review of moderate quality and below 4 is low quality.

The search algorithms, the data extraction process and the full description of the individual criteria used for grading can be found in the Supplementary Methods (Supplementary Material). All statistical analyses were performed using Stata version 13 (College Station, TX) (StatCorp 2013), and all P values were two tailed.

Patient involvement

We did not involve patients in this study. The results will be disseminated to the general public through public presentations and authors' involvement in different charities.

RESULTS

Characteristics of meta-analyses

We identified 61 eligible publications that included 171 meta-analyses of 1,354 individual study estimates (Figure 1). [13, 77-136] Of these, 604 studies were cohort (45%), whereas 750 (55%) were case-control studies, and one was a pooled analysis of cohort and case-control

studies. In all included meta-analyses, there were two to 42 study estimates combined per meta-analysis with a median of five. The median number of cases and total population in each meta-analysis was 3,271 and 265,375 respectively. The lowest number of cases in a meta-analysis was 66 and the highest was 37,423, whereas the smallest total population was 709 and highest total population was 6,445,255. In 145 out of the 171 included meta-analyses, there were more than 1,000 cases of endometrial cancer.

A total of 53 risk factors were examined in the 171 meta-analyses, which belong to eight broad categories: seven anthropometric indices (i.e. body mass index (BMI), waist to hip ratio (WHR), waist circumference (WC), weight gain (WG), weight, hip circumference and height); 19 dietary factors (e.g. dairy, fish, fruit, isoflavones, meat, nut, vegetable, alcohol, tea, coffee, acrylamide, cholesterol, fat, fatty acids, type of dietary intake, fibre, folate, glycaemic load and glycaemic index); two risk factors including physical activity and sedentary behaviour (recreational, occupational and total sitting time); six risk factors associated with pre-existing medical conditions or interventions (i.e. presence of metabolic syndrome, diabetes mellitus, hypertension, systemic lupus erythematous, polycystic ovarian syndrome and bariatric surgery); nine factors related to medication or hormonal therapy use (i.e. acetaminophen (paracetamol), aspirin, statin, metformin, bisphosphonate, non-steroidal anti-inflammatory drug, ovary stimulating drugs for subfertility, oral contraceptives and intrauterine devices); four biomarkers (i.e. adiponectin, leptin, adiponectin to leptin ratio and insulin/c-peptide level); five risk factors related to past gynaecological history (i.e. age at menarche, age at last birth, breastfeeding, fertility treatment and parity) and smoking.

Of the 171 meta-analyses, we identified 127 meta-analyses that included at least 2 cohort studies assessing 42 risk factors. Two of the 127 meta-analyses reported on endometrial

cancer mortality, the remainder on endometrial cancer incidence. These are presented in Supplementary Tables 1 and 2. Critical appraisal of the evidence in this review focuses on associations from cohort studies, which constitute the best available evidence among observational studies.

Summary effect size

With $p<0.05$ taken as the threshold of statistical significance, the summary fixed effects estimates were significant in 68 out of the 127 meta-analyses of cohort studies (54%), whereas the summary random effects were significant in 56 meta-analyses (44%) (Supplementary Table 1). At $p<0.001$, 54 (43%) and 43 (34%) meta-analyses produced significant summary results using the fixed and random effects model, respectively. At a more stringent threshold of statistical significance ($p<10^{-6}$), summary fixed effects estimates were significant in 35 (28%) meta-analyses and summary random effects were significant in 22 (17%) meta-analyses. Of the 20 meta-analyses with strongly statistically significant summary random effect estimates, 18 reported an increased risk of endometrial cancer incidence or mortality for the following risk factors: BMI, hip circumference, height, waist circumference, WHR, weight gain, weight, diabetes mellitus and metabolic syndrome. An inverse association with endometrial cancer incidence was suggested for coffee intake and parity (Supplementary Table 1). The magnitude of the observed summary random effect estimates ranged from a risk ratio of 0.39 to 3.10, with 64% of the estimates falling between 0.80 and 1.20 (Figure 2).

The association of the largest study included in each meta-analysis was nominally statistically significant in 50 meta-analyses (39%), and the relative risks of the largest

studies were more conservative than the summary random effects in 54 (43%) meta-analyses (Supplementary Table 1).

Heterogeneity between studies

The Q test for heterogeneity was significant at p≤0.10 in 44 out of 127 meta-analyses (35%). Large heterogeneity (I^2= 50-75%) was found in 27 (21%) meta-analyses and very large heterogeneity (I^2>75%) in 16 (13%) meta-analyses for ten exposures, including alcohol intake, bariatric surgery, diabetes, BMI per 5kg/m^2, BMI (overweight vs. normal), fertility treatment, glycaemic load intake, physical activity, and for Western-style and healthy-style dietary intake pattern (Supplementary Table 2).

Small study effects

Small study effects (Egger's test p-value <0.10 and where more conservative effects in the largest study of a meta-analysis compared to the summary random effects estimate were recorded) were found to be present in seven meta-analyses for risk factors including age at menarche (per two-year delay in menarcheal age), age at menarche (highest vs. lowest), BMI per 5 kg/m^2 (never HRT use, postmenopausal), dietary monounsaturated fatty acid and acrylamide intake, walking time, and coffee intake (heavy vs. non-drinker) (Supplementary Table 2).

Excess significance

Fifteen meta-analyses had evidence of excess significance bias using the largest study estimate as the plausible effect size (P<0.10). These included BMI (in young adulthood, per 5kg/m^2), weight gain (per 5kg), weight (per 5kg), coffee intake (heavy vs. non-drinker and per 1 cup/day), monounsaturated fatty acid intake (highest vs lowest), unhealthy and western

style dietary intake (highest vs lowest), alcohol intake among postmenopausal women and beer and wine intake (per 10g/day), aspirin intake, leisure time physical activity (per one hour/week), physical activity (highest vs. lowest in women with BMI≥25), bisphosphonate use (ever vs. never) and age at menarche (per two-year delay in menarcheal age). When either summary fixed, or random effects estimates were alternatively used as plausible effect sizes, excess significance bias was additionally identified for alcohol intake (high vs. low drinkers and intake from liquor) (Supplementary Table 2).

Quality assessment

We assessed the methodological quality of 61 publications that included 171 meta-analyses of observational studies, using the AMSTAR tool (Supplementary Table 3). The WCRF CUP report[116] was not included in this assessment, having already been subjected to extensive peer review processes. Only 12 meta-analyses (20%) provided "a priori" published protocols or ethics approval statements. There were at least two independent data extractors and consensus procedures in place where disagreements occurred in only 24 (40%) meta-analyses. Most meta-analyses performed a comprehensive literature search (80%), used appropriate methods to combine the findings (95%), assessed likelihood of publication bias (75%), and provided the characteristics of included studies (98%). Twenty-eight meta-analyses (46%) assessed the scientific quality of included studies and used this assessment to appropriately formulate conclusions (44%). Only two of the included meta-analyses indicated the source of funding for both original studies and meta-analysis. In total, two thirds of the meta-analyses (69%) scored between four to seven points and were considered of moderate quality, nine (15%) scored at least eight points and were considered to be high quality and ten meta-analyses (16%) scored three or less points and were considered low in quality. Low quality meta-analyses as per AMSTAR investigated the following exposures:

dietary intake of fruit and vegetables, dietary lipid intake, dietary glycaemic load and index intake, acrylamide intake, aspirin use, intrauterine device use, systemic lupus erythematous, breastfeeding, age at last birth and diabetes.

Grading the evidence

Each of the risk factors identified as being associated with endometrial cancer incidence or mortality was graded into four groups according to the strength of reported evidence in cohort studies: strong, highly suggestive, suggestive or weak evidence (Table 1). Detailed explanation of the assessment criteria is presented in Table 2 (for cohort studies only), while the results for both cohort and case-control studies are shown in Supplementary Table 4.

Only three out of 127 meta-analyses (2.4%) fulfilled the criteria of strong evidence of an association with endometrial cancer incidence. BMI was associated with an increased risk of endometrial cancer in premenopausal women (RR per 5kg/m^2 1.49; 95% CI 1.39-1.61). WHR was associated with an increased risk of endometrial cancer overall (RR per 0.1 unit 1.21; 95% CI 1.13-1.29). Parity was associated with reduced risk of endometrial cancer (RR 0.66, 95% CI 0.60-0.74) compared to nulliparous women (Table 1 and 2). These three meta-analyses scored five, six and six points on the AMSTAR assessment, respectively, and were hence considered to be of moderate methodological quality.

Thirteen meta-analyses (10.2%) presented highly suggestive evidence and evaluated associations between risk of endometrial cancer and anthropometric indices (n=10) and diabetes mellitus (n=3) (Table 1 and 2). One meta-analysis graded as highly suggestive, between diabetes and endometrial cancer [92], scored eight points on AMSTAR assessment, and was considered to be of high methodological quality. The remaining 12 were considered

to be of moderate or low quality. Suggestive evidence was found for 14 meta-analyses (11.0%) and weak evidence for 26 meta-analyses (20.5%).

Sensitivity analyses

When both cohort and case-control studies were included in the analysis (Supplementary Table 4), four additional risk factors presented strong evidence for an inverse association with endometrial cancer incidence: occupational physical activity (highest versus lowest category, RR 0.81, 95% CI 0.76-0.87), physical activity (all types, highest versus lowest category, RR 0.80, 95% CI 0.74-0.85), smoking (case-control studies only, RR 0.72, 95% CI 0.66-0.79) and smoking among postmenopausal women (RR 0.71, 95% CI 0.65-0.78). These associations provided only suggestive evidence when cohort studies alone were included. The strong association between parity and decreased endometrial cancer risk was downgraded to highly suggestive evidence (RR 0.69, 95% CI 0.65-0.73) when both cohort and case-control studies were evaluated due to the observed high between-study heterogeneity (Supplementary Table 4).

We found that 44 out of 127 meta-analyses (35%) of cohort studies retained nominal statistical significance ($p<0.05$) with a credibility ceiling of 0%. With ceilings of 10%, 15% and 20%, 31 (24%), 18 (14%) and 8 (6%) meta-analyses remained statistically significant, respectively (Supplementary Table 5). All three of the risk factors with strong evidence (BMI per 5kg/m^2 for premenopausal endometrial cancer, WHR per 0.1units and parity) remained nominally statistically significant until a 17% credibility ceiling was applied. The 11 risk factors found to have highly suggestive evidence remained nominally statistically significant until a 13% credibility ceiling was applied (Supplementary Table 5).

We identified more than one published meta-analysis assessing the same risk factors and incidence or mortality of endometrial cancer for 39 of the risk factors identified. For all duplicate meta-analyses (n=33), there was agreement on the direction, magnitude and statistical significance of the summary associations between the included and excluded meta-analyses (Supplementary Table 6). When the same evidence grading criteria were applied to these duplicate meta-analyses, the grading was similar in the majority of comparisons. Most of the excluded duplicate meta-analyses also had the same or weaker evidence grading (n=17 and 16, respectively) compared to included meta-analyses. Of the remaining excluded duplicate studies, coffee intake (n=2 meta-analyses) and intrauterine device (IUD) use (n=1) met criteria for a strong association. Glycaemic load intake (n=1) met suggestive and total fat intake (n=1) met weak evidence. The cohort studies from the excluded meta-analyses for coffee intake [10-12] were all included in the newer meta-analyses.[13, 116] The other excluded meta-analyses also had fewer cohorts included, despite being published more recently.[15, 137] Upon further comparison between the two and further investigation of the original studies, the excluded meta-analysis also reported some incorrect relative risks in the analysis. For IUD use, the included meta-analysis was a pooled analysis of 17 studies (four cohort, 13 case-control) from the Epidemiology of Endometrial Cancer Consortium, whereas the smaller excluded meta-analysis included only ten case-control studies. All the studies from the duplicate meta-analysis for glycaemic load intake (eight studies, six cohorts; suggestive evidence) were all found in the larger more recent included meta-analysis (11 studies, seven cohorts; weak evidence). Despite reaching the suggestive evidence category, the older meta-analysis had only one statistically significant study from the eight included.

DISCUSSION

Main findings and interpretation in light of existing evidence

This umbrella review, containing data extracted from 171 meta-analyses of which 127 meta-analyses included at least two cohort studies, suggests that only three meta-analyses presented strong evidence for association with endometrial cancer incidence, reflecting strongly statistically significant results and no suggestion of biases. BMI and WHR were positively associated with endometrial cancer among premenopausal women and overall, respectively, whereas parity was associated with reduced risk of total endometrial cancer. Associations between diabetes mellitus (type one or type two), height and other anthropometric indices (i.e. BMI in young adulthood, waist circumference and weight gain) with endometrial cancer were graded with highly suggestive evidence.

Obesity and endometrial cancer

The majority of meta-analyses (11/17, 64.7%) studying adiposity indices in relation to endometrial cancer incidence and mortality were supported by strong or highly suggestive evidence. Our evidence grading largely agreed with the World Cancer Research Fund Continued Update Project in 2013,[116] where body fatness was deemed to have a 'convincing causal relationship' with endometrial cancer. Similarly, the International Agency for Research on Cancer recently deemed adiposity to be causal for endometrial cancer.[138] Furthermore, our findings are in partial agreement with recent Mendelian Randomization studies, where genetically elevated BMI, but not WHR, was found to be causally associated with endometrial cancer risk.[139, 140] The mechanisms that may underlie the association of obesity with endometrial cancer are not fully characterized but likely include higher oestrogen levels in postmenopausal women, hyperinsulinaemia and a chronic inflammatory state.[4, 8, 19, 141, 142] In our review, the evidence for an association between BMI and

endometrial cancer was strong for premenopausal cancer, but was highly suggestive for postmenopausal disease due to large between-study heterogeneity, which could be due to a stronger association observed between BMI and endometrial cancer among never-users than among ever-users of HRT (RR 1.90, 95% CI 1.56-2.30, and RR 1.18, 95% CI 1.07-1.31),[78] however, the analyses by HRT use had fewer than 1,000 incident cases and were both classified as weak evidence.

Parity and endometrial cancer

We found strong evidence for a 40% reduction in endometrial cancer incidence among parous compared to nulliparous women. A large meta-analysis of 69,681 participants including 10 prospective studies, 35 case-control studies and one pooled analysis suggested a non-linear inverse relationship between parity and endometrial cancer risk.[106] Hormonal changes during pregnancy may explain this association, usually characterised by a shift to greater progesterone production with protective effects on the endometrium. The impact on the timing of endometrial carcinogenesis or for different histological subtypes is less well understood.

Diabetes and endometrial cancer

There was highly suggestive evidence that diabetes mellitus increases the risk of endometrial cancer, although the association with mortality was weak. Our analysis was in line with a previously published umbrella review by Tsilidis and colleagues that reported a summary random effects estimate of 1.97 (1.71-2.27) for endometrial cancer incidence in diabetic patients.[20, 143] Hyperinsulinaemia, which is a common phenomenon prior to diabetes onset, likely has a causal association with endometrial cancer,[4, 140] either through direct mitogenic

effects or possibly by increasing the levels of bioavailable oestrogen through a reduction in sex hormone binding globulin (SHBG) levels.

Additional risk factors for endometrial cancer

There was highly suggestive evidence that adult attained height was associated with increased risk of endometrial cancer. This finding was in partial agreement with the 2013 WCRF CUP report judgement as 'limited-suggestive'.[116] More recent data from Aune et al. with six additional studies also found height to be significantly associated with endometrial cancer risk (RR 1.15, 95% CI 1.09-1.22).[77] Although it seems biologically improbable that increased height would directly modify endometrial cancer risk, height may act as a marker for genetic and environmental factors affecting women's growth from pre-conception to growth completion. [116] There was suggestive evidence that smoking reduced the risk of endometrial cancer in cohort studies, although the evidence became strong when case-control studies were included. [107] The majority of the published cohort studies showed a reduction in risk of endometrial cancer among current or former smokers compared to never smokers.[144-153] A mechanistic link between an anti-oestrogenic effect of smoking and endometrial cancer risk has been suggested but has limited direct evidence. [154, 155] There was suggestive evidence to indicate that physical activity (any type or occupational) was inversely associated with endometrial cancer. This was in agreement with the WCRF report, which found probable causal evidence for an inverse association between physical activity and endometrial cancer.[116] The association between sedentary behaviour and endometrial cancer was supported by suggestive evidence in agreement with the WCRF report.[116] Our findings provided only suggestive evidence that coffee intake decreases the risk of endometrial cancer mainly due to evidence of excess significance bias, which was concordant with the WCRF CUP report and results from another recent review that graded

the evidence for an association as probable.[116, 156] Two further risk factors, late age at last birth and metformin use, also revealed suggestive evidence for a decrease in endometrial cancer risk. Potential biologically plausible mechanisms for why late age at last birth may protect against endometrial cancer include prolonged progesterone exposure during pregnancy being particularly beneficial in women of older age and the probability of fewer anovulatory cycles in older women who have become pregnant. [124, 157] Hypertension, despite adjustment in the meta-analysis for smoking, BMI, oral contraceptive use and parity, was the final risk factor identified within the suggestive evidence category as increasing risk of endometrial cancer. When both cohort and case-control studies were considered, hypertension had a highly suggestive association with endometrial carcinogenesis. The biological mechanism for this association remains unclear, although it has been suggested that chronic hypertension promotes cellular senescence and inhibition of apoptosis. [158, 159]

Strengths and weaknesses

This umbrella review presents the most comprehensive critical appraisal of published associations between risk factors and the risk of developing or dying from endometrial cancer. Categorisation of this evidence was based on a wide range of statistical tests and sensitivity analyses aimed to assess evidence strength and validity. The criteria selected to grade each meta-analysis by evidence level (i.e. strong, highly suggestive, suggestive or weak) is a transparent and systematic way of evaluating the strength of evidence in the literature.

Nevertheless, possible limitations and caveats should be considered. This review relies on literature searches conducted by the original authors and the results of already published systematic reviews and meta-analyses. Although it is possible that some studies were missed

in the original searches, it is unlikely that this has impacted our results, as the assessment of duplicate meta-analyses led to similar results. The statistical tests we used to explore presence of bias can only offer hints of bias, but do not prove its definitive presence or its exact source. However, our estimates are likely to be conservative, as a negative test for bias does not exclude the potential for it being present. Furthermore, the number of studies showing separate results by pre- and post-menopausal women was low. Analyses stratified by menopausal status could therefore not be conducted other than for BMI, weight gain and smoking, which may miss important exposures for a cancer type that is hormonally driven and is most commonly diagnosed in postmenopausal women. The single meta-analysis identified on association of postmenopausal hormone replacement therapy use and endometrial cancer incidence was excluded from this umbrella due to a lack of study-specific data.[160] Conducting sensitivity analyses according to the histological subtype of endometrial cancer was not possible, as this data was not provided in the individual studies, but is likely to be highly relevant.

Conclusions

This umbrella review provides a comprehensive summary of the body of published systematic reviews and meta-analyses examining risk factors and the incidence and mortality from endometrial cancer. There is a strong association between BMI (per 5kg/m^2) and waist-to-hip ratio (per 0.1 unit) and an increased risk of pre-menopausal and total endometrial cancer, respectively. A reduced risk of endometrial cancer in parous versus nulliparous women is also strongly associated. Although there are other exposures which may be associated with an increased or decreased risk of this cancer, their association is less certain and firm conclusions cannot be drawn at this time.

The identification of risk factors that are robustly associated with risk of endometrial cancer can help the identification of high-risk groups of women that would benefit from targeted prevention strategies. Our findings emphasise that obesity is a major risk factor for endometrial cancer and highlights the importance of weight control programs in mitigating the further rise in incidence of this malignancy. Hormonal and metabolic pathways that underlie the association of adiposity with endometrial cancer, as well as for diabetes and parity, require further characterisation as they may offer potential targets for preventive strategies in higher risk women.

Acknowledgements

Authors' contributions:

The study was conceived and designed by MK, EP, PMH and KT. The data was acquired and collated by OR, IK, MK, SC and analysed by OR, IK, MK, GM, SC and KT. The manuscript was drafted and revised critically for important intellectual content by all authors (OR, IK, GM, SC, MG, JN, HG, EP, PMH, KT, MK). All authors gave final approval of the version to be published and have contributed to the manuscript. Article guarantor: Dr Maria Kyrgiou. No ethical approval required.

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no relationships or activities that could appear to have influenced the submitted work.

Funding

This work was supported by Genesis Research Trust (Garfield Weston Foundation, Grant number P63522 to MK); Sigrid Jusélius Fellowship (Grant number P52483 to IK and MK); World Cancer Research Fund International Regular Grant Programme (2014/1180 to KKT); Ovarian Cancer Action (Grant number PS5827 and PSA601to MG and MK); the Imperial Experimental Cancer Medicine Centre, the Cancer Research UK Imperial Centre, Imperial Healthcare NHS Trust NIHR BRC (Grant number P45272). None of the funders have had any influence over: study design, collection, analysis and interpretation of the data, in writing the report and in the decisions to submit this article for publication.

Disclosure:

The authors have declared no conflicts of interest. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. The corresponding author MK (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

REFERENCES

1. Howlader N NA, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/ based on November 2016 SEER data submission, posted to the SEER web site, April 2017.

2. Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013. *J Natl Cancer Inst* 2017.

3. Mukhopadhaya N, Manyonda IT. The hysterectomy story in the United Kingdom. *J Midlife Health* 2013;**4**: 40-1.

4. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X, Ho GY, Einstein MH, Kaplan RC, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. *Cancer Epidemiol Biomarkers Prev* 2008;**17**: 921-9.

5. Parslov M, Lidegaard O, Klintorp S, Pedersen B, Jonsson L, Eriksen PS, Ottesen B. Risk factors among young women with endometrial cancer: a Danish case-control study. *Am J Obstet Gynecol* 2000;**182**: 23-9.

6. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, Koenig KL, Shore RE, Kim MY, Levitz M, Mittal KR, Raju U, Banerjee S, Toniolo P. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. *Br J Cancer* 2001;**84**: 975-81.

7. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N Engl J Med* 2003;**348**: 1625-38.

8. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. *Cancer Epidemiol Biomarkers Prev* 2002;**11**: 1531-43.

9. Shen D, Mao W, Liu T, Lin Q, Lu X, Wang Q, Lin F, Ekelund U, Wijndaele K. Sedentary behavior and incident cancer: a meta-analysis of prospective studies. *PLoS One* 2014;**9**: e105709.

10. Bravi F, Scotti L, Bosetti C, Gallus S, Negri E, La Vecchia C, Tavani A. Coffee drinking and endometrial cancer risk: a metaanalysis of observational studies. *Am J Obstet Gynecol* 2009;**200**: 130-5.

11. Yu X, Bao Z, Zou J, Dong J. Coffee consumption and risk of cancers: a meta-analysis of cohort studies. *BMC Cancer* 2011;**11**: 96.

12. Je Y, Giovannucci E. Coffee consumption and risk of endometrial cancer: findings from a large up-to-date meta-analysis. *Int J Cancer* 2012;**131**: 1700-10.

13. Zhou Q, Luo ML, Li H, Li M, Zhou JG. Coffee consumption and risk of endometrial cancer: a dose-response meta-analysis of prospective cohort studies. *Sci Rep* 2015;**5**: 13410.

14. Yang TO, Crowe F, Cairns BJ, Reeves GK, Beral V. Tea and coffee and risk of endometrial cancer: cohort study and meta-analysis. *Am J Clin Nutr* 2015;**101**: 570-8.

15. Wang A, Wang S, Zhu C, Huang H, Wu L, Wan X, Yang X, Zhang H, Miao R, He L, Sang X, Zhao H. Coffee and cancer risk: A meta-analysis of prospective observational studies. *Sci Rep* 2016;**6**: 33711.

16. Ioannidis JP. Why most published research findings are false. *PLoS Med* 2005;**2**: e124.

17. Ioannidis JP. Why most discovered true associations are inflated. *Epidemiology* 2008;**19**: 640-8.

18. Dwan K, Gamble C, Williamson PR, Kirkham JJ. Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review. *PLoS One* 2013;**8**: e66844.

19. Kyrgiou M, Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, Martin-Hirsch P, Tsilidis KK. Adiposity and cancer at major anatomical sites: umbrella review of the literature. *BMJ* 2017;**356**: j477.

20. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. *BMJ* 2015;**350**: g7607.

21. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. *BMJ* 2014;**348**: g2035.

22. Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. *Lancet Neurol* 2015;**14**: 263-73.

23. Bellou V, Belbasis L, Tzoulaki I, Evangelou E, Ioannidis JP. Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses. *Parkinsonism Relat Disord* 2016;**23**: 1-9.

24. Markozannes G TI, Karli D, Evangelou E, Ntzani E, Gunter M, Norat T, Ioannidis J, Tsilidis K Diet, body size, physical activity and risk of prostate cancer: An umbrella review of the evidence. *Eur J Cancer* 2016;**69**: 61-9.

25. Lee SC, Kaunitz AM, Sanchez-Ramos L, Rhatigan RM. The oncogenic potential of endometrial polyps: a systematic review and meta-analysis. *Obstet Gynecol* 2010;**116**: 1197-205.

26. Huang Y, Cai X, Qiu M, Chen P, Tang H, Hu Y, Huang Y. Prediabetes and the risk of cancer: a meta-analysis. *Diabetologia* 2014;**57**: 2261-9.

27. Wan YL, Holland C. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review. *Climacteric* 2011;**14**: 622-32.

28. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. *PLoS One* 2013;**8**: e71583.

29. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. *J Gen Intern Med* 2003;**18**: 937-47.

30. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. *Lancet Oncol* 2015;**16**: 1061-70.

31. Chaudhary S, Panda AK, Mishra DR, Mishra SK. Association of +331G/A PgR polymorphism with susceptibility to female reproductive cancer: evidence from a meta-analysis. *PLoS One* 2013;**8**: e53308.

32. Hu X, Fang Y, Zheng J, He Y, Zan X, Lin S, Li X, Li H, You C. The association between HIF-1alpha polymorphism and cancer risk: a systematic review and meta-analysis. *Tumour Biol* 2014;**35**: 903-16.

33. Huang Y, Chen H, Wang J, Bunjhoo H, Xiong W, Xu Y, Zhao J. Relationship between CCR2-V64I polymorphism and cancer risk: a meta-analysis. *Gene* 2013;**524**: 54-8.

34. Jiang DK, Yao L, Ren WH, Wang WZ, Peng B, Yu L. TP53 Arg72Pro polymorphism and endometrial cancer risk: a meta-analysis. *Med Oncol* 2011;**28**: 1129-35.

35. Kjaergaard AD, Ellervik C, Tybjaerg-Hansen A, Axelsson CK, Gronholdt ML, Grande P, Jensen GB, Nordestgaard BG. Estrogen receptor alpha polymorphism and risk of cardiovascular disease, cancer, and hip fracture: cross-sectional, cohort, and case-control studies and a meta-analysis. *Circulation* 2007;**115**: 861-71.

36. Lin G, Zhao J, Wu J, Andreevich OR, Zhang WH, Zhang Y, Yu L. Contribution of catechol-O-methyltransferase Val158Met polymorphism to endometrial cancer risk in postmenopausal women: a meta-analysis. *Genet Mol Res* 2013;**12**: 6442-53.

37. Liu JY, Yang Y, Liu ZZ, Xie JJ, Du YP, Wang W. Association between the CYP1B1 polymorphisms and risk of cancer: a meta-analysis. *Mol Genet Genomics* 2015;**290**: 739-65.

38. Pabalan N, Pineda MR, Jarjanazi H, Christofolini DM, Barbosa CP, Bianco B. Association of the +331G/A progesterone receptor gene (PgR) polymorphism with risk of endometrial cancer in Caucasian women: a meta-analysis. *Arch Gynecol Obstet* 2015;**291**: 115-22.

39. Peng Q, Mo C, Qin A, Lao X, Chen Z, Sui J, Wu J, Zhai L, Yang S, Qin X, Li S. MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis. *J Exp Clin Cancer Res* 2013;**32**: 85.

40. Tang W, He X, Chan Y, Luo Y. Lack of association between p53 codon 72 polymorphism and endometrial cancer: a meta-analysis. *Cancer Epidemiol* 2012;**36**: e153-7.

41. Teng Y, He C, Zuo X, Li X. Catechol-O-methyltransferase and cytochrome P-450 1B1 polymorphisms and endometrial cancer risk: a meta-analysis. *Int J Gynecol Cancer* 2013;**23**: 422-30.

42. Tian Z, Li YL, Zhao L, Zhang CL. Role of CYP1A2 1F polymorphism in cancer risk: evidence from a meta-analysis of 46 case-control studies. *Gene* 2013;**524**: 168-74.

43. Wang XW, Chen YL, Luo YL, Liu QY. No association between the CYP1B1 C4326G polymorphism and endometrial cancer risk: a meta-analysis. *Asian Pac J Cancer Prev* 2011;**12**: 2343-8.

44. Wang X-W, Zhong T-Y, Xiong Y-H, Lin H-B, Liu Q-Y. Lack of Association Between the CYP1A1 Ile462Val Polymorphism and Endometrial Cancer Risk: a Meta-analysis. *Asian Pac J Cancer Prev* 2012;**13**: 3717-21.

45. Wang Y, Cui M, Zheng L. Genetic polymorphisms in the estrogen receptor-alpha gene and the risk of endometrial cancer: a meta-analysis. *Acta Obstet Gynecol Scand* 2012;**91**: 911-6.

46. Wang LH, Wang X, Xu WT, Hu YL. MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis. *Tumour Biol* 2014;**35**: 3167-70.

47. Xu X, Xie Y, Lin Y, Xu X, Zhu Y, Mao Y, Hu Z, Wu J, Chen H, Zheng X, Qin J, Xie L. PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis. *Exp Ther Med* 2012;**4**: 1127-33.

48. Xu J, Lin X, Zhu H, Zhang Z, Yang B. Genetic variation of the CYP17 and susceptibility to endometrial cancer: a meta-analysis. *Mol Biol Rep* 2013;**40**: 5085-91.

49. Zhang BB, Wang DG, Xuan C, Sun GL, Deng KF. Genetic 135G/C polymorphism of RAD51 gene and risk of cancer: a meta-analysis of 28,956 cases and 28,372 controls. *Fam Cancer* 2014;**13**: 515-26.

50. Win AK, Reece JC, Ryan S. Family history and risk of endometrial cancer: a systematic review and meta-analysis. *Obstet Gynecol* 2015;**125**: 89-98.

51. Han L, Liu Y, Cao W, Yuan X, Li C. Association between cytochrome P450 1A1 MspI polymorphism and endometrial cancer risk: a meta-analysis. *Tumour Biol* 2013;**34**: 2545-50.

52. Cho YA, Kim J, Woo HD, Kang M. Dietary cadmium intake and the risk of cancer: a meta-analysis. *PLoS One* 2013;**8**: e75087.

53. Zhao HY, Duan HX, Gu Y. Meta-analysis of the cytotoxic T-lymphocyte antigen 4 gene +6230G/A polymorphism and cancer risk. *Clin Transl Oncol* 2014;**16**: 879-85.

54. Chu K-T, Song Y, Zhou J-H. No Effect of Energy Intake Overall on Risk of Endometrial Cancers: a Meta-analysis. *Asian Pac J Cancer Prev* 2015;**15**: 10293-8.

55. Dobbins M, Decorby K, Choi BC. The Association between Obesity and Cancer Risk: A Meta-Analysis of Observational Studies from 1985 to 2011. *ISRN Prev Med* 2013;**2013**: 680536.

56. Druesne-Pecollo N, Touvier M, Barrandon E, Chan DS, Norat T, Zelek L, Hercberg S, Latino-Martel P. Excess body weight and second primary cancer risk after breast cancer: a systematic review and meta-analysis of prospective studies. *Breast Cancer Res Treat* 2012;**135**: 647-54.

57. Freese KE, Kokai L, Edwards RP, Philips BJ, Sheikh MA, Kelley J, Comerci J, Marra KG, Rubin JP, Linkov F. Adipose-derived stems cells and their role in human cancer development, growth, progression, and metastasis: a systematic review. *Cancer Res* 2015;**75**: 1161-8.

58. Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. *Cochrane Database Syst Rev* 2012: Cd000402.

59. Jenabi E, Poorolajal J. The effect of body mass index on endometrial cancer: a meta-analysis. *Public Health* 2015;**129**: 872-80.

60. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. *Br J Cancer* 2006;**94**: 1221-5.

61. Lynch BM. Sedentary behavior and cancer: a systematic review of the literature and proposed biological mechanisms. *Cancer Epidemiol Biomarkers Prev* 2010;**19**: 2691-709.

62. Mueck AO, Seeger H, Rabe T. Hormonal contraception and risk of endometrial cancer: a systematic review. *Endocr Relat Cancer* 2010;**17**: R263-71.

63. Mun MJ, Kim TH, Hwang JY, Jang WC. Vitamin D receptor gene polymorphisms and the risk for female reproductive cancers: A meta-analysis. *Maturitas* 2015;**81**: 256-65.

64. Noto H, Osame K, Sasazuki T, Noda M. Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. *J Diabetes Complications* 2010;**24**: 345-53.

65. Sianou A, Galyfos G, Moragianni D, Andromidas P, Kaparos G, Baka S, Kouskouni E. The role of microRNAs in the pathogenesis of endometrial cancer: a systematic review. *Arch Gynecol Obstet* 2015;**292**: 271-82.

66. Starup-Linde J KO, Eriksen SA, Vestergaard P, Bronsveld HK, de Vries F, Andersen M, Auvinen A, Haukka J, Hjellvik V, Bazelier MT, Boer Ad, Furu K, De Bruin ML. CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysis. *Curr Drug Saf* 2013;**8**: 296-332.

67. De Ridder J, Julian-Almarcegui C, Mullee A, Rinaldi S, Van Herck K, Vicente-Rodriguez G, Huybrechts I. Comparison of anthropometric measurements of adiposity in relation to cancer risk: a systematic review of prospective studies. *Cancer Causes Control* 2016;**27**: 291-300.

68. Wang L, Li J, Shi Z. Association between Breastfeeding and Endometrial Cancer Risk: Evidence from a Systematic Review and Meta-Analysis. *Nutrients* 2015;**7**: 5697-711.

69. Li ZJ, Yang XL, Yao Y, Han WQ, Li BO. Circulating adiponectin levels and risk of endometrial cancer: Systematic review and meta-analysis. *Exp Ther Med* 2016;**11**: 2305-13.

70. Sjogren LL, Morch LS, Lokkegaard E. Hormone replacement therapy and the risk of endometrial cancer: A systematic review. *Maturitas* 2016;**91**: 25-35.

71. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. *Diabetes Care* 2012;**35**: 2402-11.

72. Ioannidis JP, Tarone R, McLaughlin JK. The false-positive to false-negative ratio in epidemiologic studies. *Epidemiology* 2011;**22**: 450-6.

73. Sterne JA, Davey Smith G. Sifting the evidence-what's wrong with significance tests? *BMJ* 2001;**322**: 226-31.

74. Johnson VE. Revised standards for statistical evidence. *Proc Natl Acad Sci U S A* 2013;**110**: 19313-7.

75. Salanti G, Ioannidis JP. Synthesis of observational studies should consider credibility ceilings. *J Clin Epidemiol* 2009;**62**: 115-22.

76. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, Tugwell P, Moher D, Bouter LM. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC medical research methodology* 2007;**7**: 10.

77. Aune D, Navarro Rosenblatt DA, Chan DS, Vingeliene S, Abar L, Vieira AR, Greenwood DC, Bandera EV, Norat T. Anthropometric factors and endometrial cancer risk: a systematic review and dose-response meta-analysis of prospective studies. *Annals of Oncology: Official Journal of the European Society for Medical Oncology* 2015;**26**: 1635-48.

78. Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2010;**19**: 3119-30.

79. Zhang Y LH, Yang S, Zhang I, Qian L, Chen X. Overweight, obesity and endometrial cancer risk: results from a systematic review and meta-analysis. *Int J Biological Markers* 2014;**29**: 21-9.

80. Keum N, Ju W, Lee DH, Ding EL, Hsieh CC, Goodman JE, Giovannucci EL. Leisure-time physical activity and endometrial cancer risk: dose-response meta-analysis of epidemiological studies. *Int J Cancer* 2014;**135**: 682-94.

81. Keum N, Greenwood DC, Lee DH, Kim R, Aune D, Ju W, Hu FB, Giovannucci EL. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. *J Natl Cancer Inst* 2015;**107**.

82. Turati F, Gallus S, Tavani A, Tramacere I, Polesel J, Talamini R, Montella M, Scotti L, Franceshi S, La Vecchia C. Alcohol and endometrial cancer risk: a case-control study and a meta-analysis. *Cancer Causes Control* 2010;**21**: 1285-96.

83. Friberg E, Orsini N, Mantzoros CS, Wolk A. Alcohol intake and endometrial cancer risk: a meta-analysis of prospective studies. *Br J Cancer* 2010;**103**: 127-31.

84. Si CJ, Shu L, Zheng PF, Zhang XY, Yu XL, Gao W, Zhang L. Dietary patterns and endometrial cancer: a meta-analysis. *Eur J Cancer Prev* 2016.

85. Bandera EV, Kushi LH, Moore DF, Gifkins DM, McCullough ML. Dietary lipids and endometrial cancer: the current epidemiologic evidence. *Cancer Causes Control* 2007;**18**: 687-703.

86. Pelucchi C, Bosetti C, Galeone C, La Vecchia C. Dietary acrylamide and cancer risk: an updated meta-analysis. *Int J Cancer* 2015;**136**: 2912-22.

87. Mulholland HG, Murray LJ, Cardwell CR, Cantwell MM. Dietary glycaemic index, glycaemic load and endometrial and ovarian cancer risk: a systematic review and meta-analysis. *Br J Cancer* 2008;**99**: 434-41.

88. Zhao J, Lyu C, Gao J, Du L, Shan B, Zhang H, Wang HY, Gao Y. Dietary fat intake and endometrial cancer risk: A dose response meta-analysis. *Medicine (Baltimore)* 2016;**95**: e4121.

89. Wu QJ, Gong TT, Wang YZ. Dietary fatty acids intake and endometrial cancer risk: a dose-response meta-analysis of epidemiological studies. *Oncotarget* 2015;**6**: 36081-97.

90. Zhou Q, Li H, Zhou JG, Ma Y, Wu T, Ma H. Green tea, black tea consumption and risk of endometrial cancer: a systematic review and meta-analysis. *Arch Gynecol Obstet* 2016;**293**: 143-55.

91. Tang NP, Li H, Qiu YL, Zhou GM, Ma J. Tea consumption and risk of endometrial cancer: a metaanalysis. *Am J Obstet Gynecol* 2009;**201**: 605 e1-8.

92. Liao C, Zhang D, Mungo C, Tompkins DA, Zeidan AM. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. *Gynecol Oncol* 2014;**135**: 163-71.

93. Zhang ZH, Su PY, Hao JH, Sun YH. The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies. *Int J Gynecol Cancer* 2013;**23**: 294-303.

94. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Giugliano D. Metabolic syndrome and endometrial cancer: a meta-analysis. *Endocrine* 2014;**45**: 28-36.

95. Bernatsky S, Ramsey-Goldman R, Foulkes WD, Gordon C, Clarke AE. Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. *Br J Cancer* 2011;**104**: 1478-81.

96. Verdoodt F, Friis S, Dehlendorff C, Albieri V, Kjaer SK. Non-steroidal anti-inflammatory drug use and risk of endometrial cancer: A systematic review and meta-analysis of observational studies. *Gynecol Oncol* 2016;**140**: 352-8.

97. Ou YJ, Chiu HF, Wong YH, Yang YH. Bisphosphonate use and the risk of endometrial cancer: a meta-analysis of observational studies. *Pharmacoepidemiol Drug Saf* 2016;**25**: 1107-15.

98. Felix AS, Gaudet MM, La Vecchia C, Nagle CM, Shu XO, Weiderpass E, Adami HO, Beresford S, Bernstein L, Chen C, Cook LS, De Vivo I, et al. Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium. *Int J Cancer* 2015;**136**: E410-22.

99. Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. *Cancer Epidemiol Biomarkers Prev* 2013;**22**: 1931-43.

100. Liu Y, Qin A, Li T, Qin X, Li S. Effect of statin on risk of gynecologic cancers: a meta-analysis of observational studies and randomized controlled trials. *Gynecol Oncol* 2014;**133**: 647-55.

101. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. *Arch Physiol Biochem* 2008;**114**: 63-70.

102. Gong TT, Wang YL, Ma XX. Age at menarche and endometrial cancer risk: a dose-response meta-analysis of prospective studies. *Sci Rep* 2015;**5**: 14051.

103. Ma X, Zhao LG, Sun JW, Yang Y, Zheng JL, Gao J, Xiang YB. Association between breastfeeding and risk of endometrial cancer: a meta-analysis of epidemiological studies. *Eur J Cancer Prev* 2015.

104. Saso S, Louis LS, Doctor F, Hamed AH, Chatterjee J, Yazbek J, Bora S, Abdalla H, Ghaem-Maghami S, Thum MY. Does fertility treatment increase the risk of uterine cancer? A meta-analysis. *Eur J Obstet Gynecol Reprod Biol* 2015;**195**: 52-60.

105. Siristatidis C, Sergentanis TN, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I, Psaltopoulou T, Skalkidou A, Petridou ET. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-analysis. *Hum Reprod Update* 2013;**19**: 105-23.

106. Wu QJ, Li YY, Tu C, Zhu J, Qian KQ, Feng TB, Li C, Wu L, Ma XX. Parity and endometrial cancer risk: a meta-analysis of epidemiological studies. *Sci Rep* 2015;**5**: 14243.

107. Zhou B, Yang L, Sun Q, Cong R, Gu H, Tang N, Zhu H, Wang B. Cigarette smoking and the risk of endometrial cancer: a meta-analysis. *Am J Med* 2008;**121**: 501-8 e3.

108. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod Update* 2014;**20**: 748-58.

109. Lin T, Zhao X, Kong WM. Association between adiponectin levels and endometrial carcinoma risk: evidence from a dose-response meta-analysis. *BMJ Open* 2015;**5**: e008541.

110. Bandera EV, Kushi LH, Moore DF, Gifkins DM, McCullough ML. Fruits and vegetables and endometrial cancer risk: a systematic literature review and meta-analysis. *Nutr Cancer* 2007;**58**: 6-21.

111. Bandera EV, Kushi LH, Moore DF, Gifkins DM, McCullough ML. Consumption of animal foods and endometrial cancer risk: a systematic literature review and meta-analysis. *Cancer Causes Control* 2007;**18**: 967-88.

112. Bandera EV, Kushi LH, Moore DF, Gifkins DM, McCullough ML. Association between dietary fiber and endometrial cancer: a dose-response meta-analysis. *Am J Clin Nutr* 2007;**86**: 1730-7.

113. Gong TT, Li D, Wu QJ, Wang YZ. Cholesterol consumption and risk of endometrial cancer: a systematic review and dose-response meta-analysis of observational studies. *Oncotarget* 2016;**7**: 16996-7008.

114. Schwingshackl L, Hoffmann G. Adherence to Mediterranean diet and risk of cancer: an updated systematic review and meta-analysis of observational studies. *Cancer Med* 2015;**4**: 1933-47.

115. Wu L, Wang Z, Zhu J, Murad AL, Prokop LJ, Murad MH. Nut consumption and risk of cancer and type 2 diabetes: a systematic review and meta-analysis. *Nutr Rev* 2015;**73**: 409-25.

116. World Cancer Research Fund International/American Institute for Cancer Research Continuous Update Project Report. Diet, Nutrition, Physical Activity, and Endometrial Cancer 2013.

117. Upala S, Anawin S. Bariatric surgery and risk of postoperative endometrial cancer: a systematic review and meta-analysis. *Surg Obes Relat Dis* 2015;**11**: 949-55.

118. Gong TT, Wu QJ, Wang YL, Ma XX. Circulating adiponectin, leptin and adiponectin-leptin ratio and endometrial cancer risk: Evidence from a meta-analysis of epidemiologic studies. *Int J Cancer* 2015;**137**: 1967-78.

119. Jordan SJ, Na R, Johnatty SE, Wise LA, Adami HO, Brinton LA, Chen C, Cook LS, Dal Maso L, De Vivo I, Freudenheim JL, Friedenreich CM, et al. Breastfeeding and Endometrial Cancer Risk: An Analysis From the Epidemiology of Endometrial Cancer Consortium. *Obstet Gynecol* 2017;**129**: 1059-67.

120. Sieri S, Krogh V. Dietary glycemic index, glycemic load and cancer: An overview of the literature. *Nutr Metab Cardiovasc Dis* 2017;**27**: 18-31.

121. Aune D, Sen A, Vatten LJ. Hypertension and the risk of endometrial cancer: a systematic review and meta-analysis of case-control and cohort studies. *Sci Rep* 2017;**7**: 44808.

122. Ding YY, Yao P, Verma S, Han ZK, Hong T, Zhu YQ, Li HX. Use of acetaminophen and risk of endometrial cancer: evidence from observational studies. *Oncotarget* 2017;**8**: 34643-51.

123. Du L, Wang Y, Zhang H, Zhang H, Gao Y. Folate intake and the risk of endometrial cancer: A meta-analysis. *Oncotarget* 2016;**7**: 85176-84.

124. Setiawan VW, Pike MC, Karageorgi S, Deming SL, Anderson K, Bernstein L, Brinton LA, Cai H, Cerhan JR, Cozen W, Chen C, Doherty J, et al. Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium. *Am J Epidemiol* 2012;**176**: 269-78.

125. Zhou Q, Guo P, Li H, Chen XD. Does alcohol consumption modify the risk of endometrial cancer? A dose-response meta-analysis of prospective studies. *Arch Gynecol Obstet* 2017;**295**: 467-79.

126. Li X, Zhao J, Li P, Gao Y. Dairy Products Intake and Endometrial Cancer Risk: A Meta-Analysis of Observational Studies. *Nutrients* 2017;**10**.

127. Grosso G, Bella F, Godos J, Sciacca S, Del Rio D, Ray S, Galvano F, Giovannucci EL. Possible role of diet in cancer: systematic review and multiple meta-analyses of dietary patterns, lifestyle factors, and cancer risk. *Nutr Rev* 2017;**75**: 405-19.

128. Yang J, Zhu Q, Liu Q, Wang Y, Xie W, Hu L. Statin use and endometrial cancer risk: a meta-analysis. *Oncotarget* 2017;**8**: 62425-34.

129. Tang YL, Zhu LY, Li Y, Yu J, Wang J, Zeng XX, Hu KX, Liu JY, Xu JX. Metformin Use Is Associated with Reduced Incidence and Improved Survival of Endometrial Cancer: A Meta-Analysis. *Biomed Res Int* 2017;**2017**: 5905384.

130. Skalkidou A, Sergentanis TN, Gialamas SP, Georgakis MK, Psaltopoulou T, Trivella M, Siristatidis CS, Evangelou E, Petridou E. Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility. *Cochrane Database Syst Rev* 2017;**3**: Cd010931.

131. Jiang L, Hou R, Gong TT, Wu QJ. Dietary fat intake and endometrial cancer risk: dose-response meta-analysis of epidemiological studies. *Sci Rep* 2015;**5**: 16693.

132. Schmid D, Behrens G, Keimling M, Jochem C, Ricci C, Leitzmann M. A systematic review and meta-analysis of physical activity and endometrial cancer risk. *Eur J Epidemiol* 2015;**30**: 397-412.

133. Schmid D, Leitzmann MF. Television viewing and time spent sedentary in relation to cancer risk: a meta-analysis. *J Natl Cancer Inst* 2014;**106**.

134. Qiao Y, Yang T, Gan Y, Li W, Wang C, Gong Y, Lu Z. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. *BMC Cancer* 2018;**18**: 288.

135. Zhong XS, Ge J, Chen SW, Xiong YQ, Ma SJ, Chen Q. Association between Dietary Isoflavones in Soy and Legumes and Endometrial Cancer: A Systematic Review and Meta-Analysis. *J Acad Nutr Diet* 2016.

136. Neill AS, Nagle CM, Protani MM, Obermair A, Spurdle AB, Webb PM, Australian National Endometrial Cancer Study G. Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis. *Int J Cancer* 2013;**132**: 1146-55.

137. Lafranconi A, Micek A, Galvano F, Rossetti S, Del Pup L, Berretta M, Facchini G. Coffee Decreases the Risk of Endometrial Cancer: A Dose-Response Meta-Analysis of Prospective Cohort Studies. *Nutrients* 2017;**9**.

138. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body Fatness and Cancer--Viewpoint of the IARC Working Group. *N Engl J Med* 2016;**375**: 794-8.

139. Painter JN, O'Mara TA, Marquart L, Webb PM, Attia J, Medland SE, Cheng T, Dennis J, Holliday EG, McEvoy M, Scott RJ, Ahmed S, et al. Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. *Cancer Epidemiol Biomarkers Prev* 2016;**25**: 1503-10.

140. Nead KT, Sharp SJ, Thompson DJ, Painter JN, Savage DB, Semple RK, Barker A, Perry JR, Attia J, Dunning AM, Easton DF, Holliday E, et al. Evidence of a Causal Association Between Insulinemia and Endometrial Cancer: A Mendelian Randomization Analysis. *J Natl Cancer Inst* 2015;**107**.

141. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. *Nat Rev Cancer* 2011;**11**: 886-95.

142. Kalliala I, Markozannes, G., Gunter, M., Paraskevaidis, E., Gabra, H., Mitra, A., Terzidou, V., Bennett, P., Martin-Hirsch, P., Tsilidis, K., Kyrgiou, M. Obesity and gynaecological and obstetrical conditions: an umbrella review of the literature. *In press, BMJ* 2017.

143. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and Cancer: A consensus report. *CA Cancer J Clin* 2010;**60**: 207-21.

144. Loerbroks A, Schouten LJ, Goldbohm RA, van den Brandt PA. Alcohol consumption, cigarette smoking, and endometrial cancer risk: results from the Netherlands Cohort Study. *Cancer Causes Control* 2007;**18**: 551-60.

145. Viswanathan AN, Feskanich D, De Vivo I, Hunter DJ, Barbieri RL, Rosner B, Colditz GA, Hankinson SE. Smoking and the risk of endometrial cancer: results from the Nurses' Health Study. *Int J Cancer* 2005;**114**: 996-1001.

146. Furberg AS, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. *Int J Cancer* 2003;**104**: 669-76.

147. Folsom AR, Demissie Z, Harnack L. Glycemic index, glycemic load, and incidence of endometrial cancer: the Iowa women's health study. *Nutr Cancer* 2003;**46**: 119-24.

148. Engeland A, Bjorge T, Haldorsen T, Tretli S. Use of multiple primary cancers to indicate associations between smoking and cancer incidence: an analysis of 500,000 cancer cases diagnosed in Norway during 1953-93. *Int J Cancer* 1997;**70**: 401-7.

149. Lacey JV, Jr., Leitzmann MF, Chang SC, Mouw T, Hollenbeck AR, Schatzkin A, Brinton LA. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort. *Cancer* 2007;**109**: 1303-11.

150. Al-Zoughool M, Dossus L, Kaaks R, Clavel-Chapelon F, Tjonneland A, Olsen A, Overvad K, Boutron-Ruault MC, Gauthier E, Linseisen J, Chang-Claude J, Boeing H, et al. Risk of endometrial cancer in relationship to cigarette smoking: results from the EPIC study. *Int J Cancer* 2007;**121**: 2741-7.

151. Setiawan VW, Pike MC, Kolonel LN, Nomura AM, Goodman MT, Henderson BE. Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study. *Am J Epidemiol* 2007;**165**: 262-70.

152. Lindemann K, Vatten LJ, Ellstrom-Engh M, Eskild A. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. *Br J Cancer* 2008;**98**: 1582-5.

153. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. *Lancet* 2005;**365**: 1543-51.

154. Michnovicz JJ, Hershcopf RJ, Naganuma H, Bradlow HL, Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. *N Engl J Med* 1986;**315**: 1305-9.

155. Williams RR, Horm JW. Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: interview study from the Third National Cancer Survey. *J Natl Cancer Inst* 1977;**58**: 525-47.

156. Grosso G, Godos J, Galvano F, Giovannucci EL. Coffee, Caffeine, and Health Outcomes: An Umbrella Review. *Annu Rev Nutr* 2017;**37**: 131-56.

157. Karageorgi S, Hankinson SE, Kraft P, De Vivo I. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004. *Int J Cancer* 2010;**126**: 208-16.

158. Hamet P. Cancer and hypertension: a potential for crosstalk? *J Hypertens* 1997;**15**: 1573-7.

159. Soler M, Chatenoud L, Negri E, Parazzini F, Franceschi S, la Vecchia C. Hypertension and hormone-related neoplasms in women. *Hypertension* 1999;**34**: 320-5.

160. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. *Obstet Gynecol* 1995;**85**: 304-13.

Table 1: Summary of evidence grading for meta-analyses of risk factors associated with endometrial cancer incidence or mortality — cohort studies only*

Evidence	Criteria used	Decreased Risk	Increased Risk
Strong	$P<10^{-6}$‖; >1,000 cases; $I^2<50\%$; no small study effects¶; prediction interval excludes the null value; no excess significance bias†	***Past gynaecological history***	***Anthropometric indices***
		Parity: parous vs. nulliparous	BMI per 5kg/m^2: premenopausal
			Waist-to-hip ratio: per 0.1 units
Highly suggestive	$P<10^{-6}$‖; >1,000 cases; P<0.05 of the largest study in a meta-analysis	None	***Anthropometric indices***
			BMI iya: per 5kg/m^2
			BMI per 5kg/m^2 increment
			BMI per 5kg/m^2: Type II
			BMI per 5kg/m^2: postmenopausal
			BMI per 5kg/m^2: Type I
			BMI: > 30 vs. < 25
			Height: per 10cm
			Waist circumference: per 10 cm
			Weight gain: per 5kg
			Weight: per 5kg
			Pre-existing medical conditions
			Diabetes mellitus (T1/T2): present vs. absent (HR)
			Diabetes mellitus (T1/T2): present vs. absent (IRR)
			Diabetes mellitus (T1/T2): present vs. absent (SIR)
Suggestive	$P<10^{-3}$‖; >1,000 cases	***Dietary intake***	***Physical activity and sedentary behaviour***
		Coffee intake: highest vs. lowest category	Sedentary behaviour: highest vs. lowest category
		Coffee intake: per 1 cup/day	***Pre-existing medical conditions and interventions***
		Physical activity and sedentary behaviour	Hypertension
		Occupational physical activity: highest vs. lowest category	Diabetes mellitus (T1/T2): present vs. absent (RR)

		Physical activity: highest vs. lowest category	
		Past gynaecological history	
		Age at last birth: per 5-year increment	
		Age at menarche: delay in menarcheal age, per 2-year delay	
		Age at menarche: highest vs. lowest category	
		Use of medical / hormonal therapy	
		Metformin use: ever vs. never	
		Oral contraceptive: ever vs. never use	
		Smoking	
		Smoking: ever vs. never**	
		Smoking: ever vs. never, postmenopausal	
[illegible]	P<0.05‖	***Dietary intake***	***Anthropometric indices***
		Animal fat intake: per 10g/1000kcal	BMI: per 5kg/m^2, ever HRT
		Animal-based fat intake: per 30g increase a day	BMI: per 5kg/m^2, never HRT
		Carbohydrate intake: per 100g/day	BMI: > 25 vs. < 25
		Decaffeinated coffee intake: per 1 cup/day	BMI: per 5kg/m^2, mortality
		Fibre intake: per 10g/day	Hip circumference: per 10cm
		Healthy dietary intake: highest vs. lowest category	Weight gain: per 5kg, ever HRT
		Monounsaturated fatty acid intake: highest vs. lowest category	Weight gain: per 5kg, never HRT
		Total fat intake: per 30g increase a day	***Dietary intake***
		Physical activity and sedentary behaviour	Glycaemic load intake: highest vs. lowest category, obese
		Leisure time physical activity: per 1hour/week	Glycaemic load intake: per 50 units/day
		Pre-existing medical conditions and interventions	Western style pattern dietary intake: highest vs. lowest
		Bariatric surgery: yes vs. no	***Pre-existing medical conditions***
		Use of medical / hormonal therapy	Diabetes mellitus (T1/T2): present vs. absent, mortality
		Bisphosphonate use: ever vs. never	Metabolic syndrome: present vs. absent

		Past gynaecological history	***Past gynaecological history***
		Breastfeeding: longest vs. shortest duration	IVF done: ever vs. never
		Smoking	
		Smoking: per 20 cigarettes/day increment**	

Abbreviations: BMI, body mass index; BMI iya, Body mass index in young adulthood; EC, endometrial cancer; ECM, endometrial cancer mortality; HR, hazard ratio; HRT, hormone replacement therapy; IRR, incidence rate ratio; IVF, in-vitro fertilization; RR, relative risk; SIR, standardised incidence ratio; T1T2, Type 1 or Type 2 diabetes mellitus.

Key:
*only meta-analyses meeting at least weak grade of evidence listed
**only prospective studies were included
‖P indicates the p-values of the meta-analysis random effects model
¶Small study effect is based on the P-value from the Egger's regression asymmetry test (P>0.1) where the random effects summary estimate was larger compared to the point estimate of the largest study in a meta-analysis
†Based on the p-value (P>0.1) of the excess significance test using the largest study (smallest standard error) in a meta-analysis as the plausible effect size.

Table 2: Details of evidence grading for meta-analyses of risk factors for endometrial cancer incidence or mortality — only cohort studies included*

Exposure	Exposure contrast	N[b]	Sample size Cases/Cohort	Largest study[c]	Random effects summary RR (95% CI)[d]	Random P-value[e]	95% Prediction interval	Egger's P[f]	I^2 (%)	Excess significance[g]		Evidence Grading[j]
										O/E[h]	P-value[i]	
Strong evidence												
Anthropometric indices												
BMI	per 5kg/m^2: PrMP	6	5,981 / 2,558,935	1.53 (1.48-1.58)	1.49 (1.39-1.61)	3.10E-27	1.27-1.76	0.56	20	5/4.2	0.67	Strong
WHR	per 0.1 units	5	2,447 / 394,340	1.33 (1.18-1.51)	1.21 (1.13-1.29)	1.00E-08	1.09-1.34	0.54	0	3/4.4	NP	Strong
Past gynaecological history												
Parity	parous vs. nulliparous	7	2,465 / 695,415	0.65 (0.54-0.77)	0.66 (0.60-0.74)	2.50E-14	0.58-0.76	0.98	0	5/6.2	NP	Strong
Highly suggestive evidence												
Anthropometric indices												
BMI	iya per 5kg/m^2	9	4,345 / 631,915	1.23 (1.11-1.35)	1.45 (1.28-1.64)	1.90E-09	0.98-2.15	0.41	75	8/5.2	0.09	Highly suggestive
BMI	per 5kg/m^2 increment	28	22,320 / 6,445,255	1.65 (1.60-1.71)	1.54 (1.47-1.61)	<1E-100	1.26-1.89	0.35	81	26/25.2	1.00	Highly suggestive
BMI	per 5kg/m^2: Type II	3	1,059 / 1,102,927	1.35 (1.25-1.46)	1.59 (1.29-1.78)	5.70E-07	0.24-9.67	0.52	76	3/1.5	0.25	Highly suggestive
BMI	per 5kg/m^2: PoMP	6	10,075 / 2,558,935	1.51 (1.45-1.58)	1.60 (1.40-1.83)	1.40E-11	1.01-2.53	0.88	89	6/5.0	0.6	Highly suggestive
BMI	per 5kg/m^2: Type I	3	7,125 / 1,102,927	1.58 (1.53-1.62)	1.75 (1.51-2.03)	1.80E-13	0.30-10.3	0.26	82	3/2.9	1.00	Highly suggestive
BMI	> 30 vs. < 25	6	4,327 / 1,485,506	2.73 (2.48-2.99)	3.10 (2.63-3.65)	<1E-100	1.92-5.00	0.24	66	6/6.0	1.00	Highly suggestive
Height	per 10cm	9	20,519 / 3,454,681	1.11 (1.07-1.15)	1.15 (1.09-1.22)	4.00E-07	0.99-1.34	0.60	61	6/4.6	0.55	Highly suggestive
Waist circumference	per 10 cm	4	1,524 / 315,770	1.28 (1.19-1.37)	1.27 (1.17-1.39)	7.30E-08	0.88-1.85	0.59	70	3/2.9	1.00	Highly suggestive
Weight gain	per 5kg	7	2,806 / 460,901	1.17 (1.12-1.22)	1.16 (1.12-1.20)	3.70E-18	1.06-1.27	0.95	47	6/2.8	0.02	Highly suggestive
Weight	per 5kg	7	1,778 / 342,382	1.11 (1.08-1.15)	1.17 (1.13-1.22)	7.70E-15	1.04-1.31	0.29	62	6/1.0	<0.01	Highly suggestive
Pre-existing medical conditions and interventions												

Diabetes mellitus	(T1T2): present vs. absent, HR	7	5,310 / 3,158,753	1.38 (1.23-1.55)	1.44 (1.27-1.64)	1.80E-08	0.99-2.09	0.36	66	7/6.1	0.60	Highly suggestive
Diabetes mellitus	(T1T2): present vs. absent, IRR	2	9,070 / NA	1.61 (1.51-1.72)	1.61 (1.51-1.71)	<1E-100	NA	NA	0	2/2.0	1.00	Highly suggestive
Diabetes mellitus	(T1T2): present vs. absent, SIR	8	1,041 / 332,372	2.22 (2.01-2.45)	1.77 (1.47-2.15)	4.0E-09	1.03-3.05	0.66	80	6/4.6	0.72	Highly suggestive
Suggestive evidence												
Dietary Intake												
Coffee intake	HvL	14	10,100 / 1,557,395	0.92 (0.82-1.04)	0.76 (0.69-0.84)	1.90E-07	0.60-0.96	0.04	29	7/3.0	0.02	Suggestive
Coffee intake	per 1 cup/day	7	3,538 / 506,241	0.94 (0.91-0.97)	0.93 (0.91-0.96)	1.3 E-06	0.89-0.98	0.41	11	4/0.84	<0.01	Suggestive
Pre-existing medical conditions and interventions												
Diabetes mellitus	(T1T2): present vs. absent, RR	6	1,080 / 139,941	1.43 (0.98-2.09)	1.89 (1.46-2.45)	1.5E-06	1.10-3.26	0.93	20	3/5.4	NP	Suggestive
Hypertension	yes vs. no	6	1,469 / 153,231	1.24 (1.03-1.50)	1.32 (1.12-1.56)	9.0E-04	0.85-2.06	0.78	47	3/2.5	0.70	Suggestive
Physical activity and Sedentary behaviour												
Occupational PA	HvL	9	10,178 / 1,846,134	0.76 (0.67-0.85)	0.83 (0.76-0.91)	2.90E-05	0.75-0.93	0.37	1	1/5.1	NP	Suggestive
Physical activity	HvL	19	13,809 / 2,176,294	0.76 (0.67-0.85)	0.84 (0.77-0.92)	9.50E-05	0.67-1.05	0.46	29	4/11.9	NP	Suggestive
Sedentary behaviour	HvL	3	1,302 / 146,746	1.40 (1.03-1.89)	1.57 (1.29-1.91)	9.00E-06	0.43-5.67	0.45	0	3/2.7	1.00	Suggestive
Use of medical / hormonal therapy												
Metformin use	ever vs. never	3	3,685 / 755,579	0.84 (0.76-0.93)	0.85 (0.77-0.93)	6.0E-04	0.47-1.55	0.03	0	1/1.9	0.30	Suggestive
Oral contraceptive	ever vs. never use	4	1,513 / 624,556	0.65 (0.56-0.75)	0.57 (0.45-0.74)	1.30E-05	0.22-1.52	0.31	57	3/3.4	NP	Suggestive
Past gynaecological history												
Age at last birth	per 5-year increment	4	1,891 / 7,181	0.89 (0.81-0.99)	0.90 (0.85-0.95)	2.0E-04	0.80-1.02	0.74	0	2/1.0	0.21	Suggestive
Age at menarche	delay in menarcheal age	5	3,773 / 829,958	0.98 (0.97-1.00)	0.96 (0.94-0.98)	1.90E-04	0.90-1.02	0.03	56	4/0.3	<0.01	Suggestive
Age at menarche	HvL	7	4,514 / 938,970	0.80 (0.65-0.97)	0.68 (0.57-0.81)	1.70E-05	0.42-1.09	0.05	50	5/5.2	NP	Suggestive
Smoking												
Smoking	ever vs. never	10	3,173 / 448,586	0.73 (0.63-0.83)	0.81 (0.74-0.88)	2.20E-06	0.69-0.94	0.46	11	3/7.8	NP	Suggestive
Smoking	ever vs. never, PoMP	5	1,852 / 276,643	0.77 (0.65-0.92)	0.76 (0.70-0.87)	7.20E-05	0.62-0.95	0.74	0	2/3.9	NP	Suggestive
Weak evidence												
Anthropometric indices												

BMI	per 5kg/m^2, ever HRT (PoMP)	6	791 / 679,271	1.25 (1.05-1.47)	1.18 (1.07-1.31)	1.70E-03	1.02-1.37	0.77	0	1/1.7	NP	Weak
BMI	per 5kg/m^2, never HRT (PoMP)	3	699 / 360,326	1.61 (1.41-1.85)	1.90 (1.56-2.30)	9.20E-11	0.19-18.6	0.01	77	3/2.9	1.00	Weak
BMI	> 25 vs. < 25	7	4,548 / 1,489,424	1.79 (1.65-1.95)	1.60 (1.10-2.33)	0.01	0.42-6.09	0.71	96	7/6.9	1.00	Weak
BMI	per 5kg/m^2: ECM	3	962 / 1,781,648	1.42 (1.33-1.63)	1.46 (1.29-1.65)	1.70E-09	0.48-4.48	0.64	29	2/2.0	1.00	Weak
Hip circumference	per 10cm	2	831 / 255,650	1.32 (1.20-1.45)	1.29 (1.19-1.41)	2.90E-09	NA	NA	0	1/1.65	NP	Weak
Weight gain	per 5kg, ever HRT (PoMP)	2	334 / 35,333	1.09 (1.00-1.18)	1.09 (1.02-1.17)	0.01	NA	NA	0	1/0.2	0.18	Weak
Weight gain	per 5kg, never HRT (PoMP)	2	285 / 33,340	1.36 (1.25-1.49)	1.38 (1.28-1.49)	3.60E-17	NA	NA	0	2/1.0	0.50	Weak
Dietary Intake												
Animal fat intake	per 10g/1000kcal	2	437 / 26,767	0.77 (0.62-0.95)	0.78 (0.63-0.96	0.02	NA	NA	0	1/1.1	NP	Weak
Animal fat intake	per 30g increase a day	3	2,193 / 427,317	0.97 (0.86-1.09)	0.92 (0.86-0.99)	0.03	0.58-1.47	0.40	0	1.0.2	0.21	Weak
Carbohydrate intake	per 100g/day	5	2,629 / 475,185	1.20 (0.97-1.50)	1.18 (1.02-1.37)	0.03	0.93-1.50	0.72	0	0/3.05	0.01	Weak
Decaffeinated coffee	per 1 cup/day	3	2,585 / 339,898	0.93 (0.87-0.99)	0.92 (0.87-0.97)	1.3 E-03	0.66-1.28	0.50	0	2/0.65	0.06	Weak
Fibre intake	per 10g/day	2	1,379 / 356,498	1.10 (0.98-1.23)	1.09 (1.00-1.19)	0.04	NA	NA	0	0/0.56	0.38	Weak
Healthy dietary intake	HvL	4	706 / 89,935	0.46 (0.37-0.56)	0.67 (0.47-0.96)	0.03	0.14-3.24	0.03	77	2/3.9	NP	Weak
MUFA intake	HvL	3	3,503 / 524,583	0.95 (0.81-1.10)	0.85 (0.73-0.98)	0.03	0.19-3.70	0.14	43	2/0.5	0.07	Weak
Total fat intake	per 30g increase a day	4	3,185 / 540,995	0.96 (0.92-1.02)	0.95 (0.91-0.98)	2.00E-03	0.88-1.02	0.88	0	1/0.4	0.34	Weak
Glycaemic load intake	HvL, obese	4	2,159 / 412,805	1.16 (0.73-1.85)	1.55 (1.18-2.03)	1.50E-03	0.86-2.80	0.40	0	2/1.9	1.00	Weak
Glycaemic load intake	per 50 units/day	6	3,869 / 658,985	1.14 (0.96-1.34)	1.12 (1.03-1.22)	7.6 E-03	1.00-1.26	0.68	0	0/2.65	0.03	Weak
Western diet intake	HvL	5	1,333 / 104,036	1.09 (0.93-1.29)	1.60 (1.11-2.30)	0.01	0.43-5.99	0.36	86	3/0.6	0.01	Weak
Physical activity and Sedentary behaviour												
Leisure time PA	per 1hour/week	2	1,202 / 95,627	0.97 (0.95-1.00)	0.96 (0.93-0.99)	5.70E-03	NA	NA	35	2/0.1	<0.01	Weak
Pre-existing medical conditions and interventions												
Bariatric surgery	yes vs. no	3	12,288 / 958,988	0.48 (0.43-0.55)	0.39 (0.19-0.79)	8.60E-03	0-1314.22	0.74	80	2/2.5	NP	Weak
Diabetes mellitus	yes vs. no, RR, ECM	3	540 / 693,698	1.33 (0.92-1.90)	1.47 (1.06-2.04)	0.02	0.18-12.2	0.58	0	1/1.2	NP	Weak
Metabolic syndrome	present vs. absent	2	937 / 303,997	1.37 (1.28-1.46)	1.37 (1.29-1.47)	1.30E-21	NA	NA	0	1/1.1	NP	Weak
Use of medical / hormonal therapy												
IUD use (any type)	ever vs. never	17	8,575 / 23,708	0.96 (0.95-0.98)	0.83 (0.72-0.96)	0.01	0.52-1.32	0.07	68	4/1.1	0.02	Weak

Bisphosphonate use	ever vs. never	4	109 / 48,657	0.80 (0.64-1.00)	0.74 (0.59-0.92)	8.10E-03	0.39-1.38	0.98	12	2/0.4	0.05	Weak
Past gynaecological history												
Breastfeeding	longest vs. shortest duration	3	1,255 / 589,866	0.77 (0.54-1.11)	0.62 (0.41-0.94)	0.02	0.01-30.3	0.10	37	1/1.7	NP	Weak
IVF done	ever vs. never	5	105 / 724,372	1.42 (0.63-3.21)	0.92 (0.50-1.71)	0.80	0.27-3.10	0.80	0	1/2.4	NP	Weak
Smoking												
Smoking	per 20 cigarettes/day increment	6	1,864 / 279,107	0.74 (0.66-0.84)	0.84 (0.71-0.99)	0.03	0.54-1.31	0.97	59	2/4.3	NP	Weak

Abbreviations: BMI, body mass index; BMI iya, body mass index in young adulthood; CI, confidence interval; ECM, endometrial cancer mortality; HR, hazard ratio; HRT, hormone replacement therapy; IRR, incidence rate ratio; IUD, intra-uterine device; MUFA, monounsaturated fatty acids; NA, not available; NP, not pertinent, because the estimated is larger than the observed, and there is no evidence of excess statistical significance based on the assumption made for the plausible effect size; PA, physical activity; PoMP, postmenopausal; PrMP, premenopausal; RR, relative risk; SIR, standardised incidence ratio; T1T2, Type 1 or Type 2 diabetes mellitus; WHR, waist-to-hip ratio.

Key:
*only meta-analyses meeting at least weak grade of evidence listed
* Number of studies
# Relative risk and 95% confidence interval of largest study (smallest standard error) in each meta-analysis
¥ Random effects refer to summary risk ratio (95% confidence interval) using the random-effects model
‖ P value of summary random effects estimate
∞ P-value from the Egger's regression asymmetry test
§ Expected number of statistically significant studies using the point estimate of the largest study (smallest standard error) as the plausible effect size
α Observed/Expected number of statistically significant studies
ˇP value of the excess statistical significance test
All statistical tests were two-sided
¶Small study effect is based on the P-value from the Egger's regression asymmetry test (P>0.1) where the random effects summary estimate was larger compared to the point estimate of the largest study in a meta-analysis
†Based on the p-value (P>0.1) of the excess significance test using the largest study (smallest standard error) in a meta-analysis as the plausible effect size.

**Summary of evidence grading criteria:

Weak	P<0.05‖
Suggestive	P<10^{-3}‖; >1,000 cases
Highly suggestive	P<10^{-6}‖; >1,000 cases; P<0.05 of the largest study in a meta-analysis
Strong	P<10^{-6}‖; >1,000 cases; P<0.05 of the largest study in a meta-analysis; I^2<50%; no small study effect¶; prediction interval excludes the null value; no excess

	significance bias[†]

FIGURE TITLES

Figure 1. Flow diagram of selection of meta-analyses regarding risk factors for endometrial cancer.

Figure 2. The association between summary random effects estimates and inverse of variance in meta-analyses, stratified by type of exposure-outcome pair.



Figure 1. Flow diagram of selection of meta-analyses regarding risk factors for endometrial cancer.



Figure 2. The association between summary random effects estimates and inverse of variance in meta-analyses, stratified by type of exposure-outcome pair

BD Accuri™ C6 Plus Personal Flow Cytometer

BD FACSCelesta™ Cell Analyzer

BD LSRFortessa™ X-20 Cell Analyzer

BD FACSMelody™ Cell Sorter

FlowJo™ Software

One of the largest portfolios of reagents

Discover more >

BD